Zhejiang Huahai Pharmaceutical Co Ltd

Zhejiang Huahai Pharmaceutical maintains a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.42, suggesting it can cover short-term obligations but with limited buffer. Free cash flow is negative at -295.6 million CNY, reflecting capital expenditure outpacing operating cash flow. The company's profitability is moderate, with a return on equity of 12.58% and a return on assets of 5.52%. These figures are in line with industry norms for pharmaceutical firms, which typically exhibit stable but not high returns due to regulatory and R&D costs. Operating income of 1.46 billion CNY and net income of 1.12 billion CNY indicate a healthy margin, though the gross profit margin of 60.9% suggests room for improvement in cost control. Zhejiang Huahai Pharmaceutical's revenue is concentrated in its domestic market, with no material international operations disclosed. The company operates in a single business segment, focusing on pharmaceutical products. This lack of diversification increases exposure to domestic regulatory and economic shifts. The company's growth trajectory is mixed. Revenue for the latest period was 9.55 billion CNY, but no year-over-year growth rate is provided. Analysts have issued a mean price target of 17.33 CNY, with a median of 18.00 CNY, suggesting a cautious outlook. The absence of strong-buy ratings and the presence of only two buy ratings indicate limited upside consensus. Risk factors include liquidity constraints, as the company has negative net cash after subtracting total debt. The risk of dilution is assessed as low, with no recent share issuance or ATM/shelf disclosures reported. However, the negative free cash flow and high capital expenditure of 1.85 billion CNY raise concerns about long-term financial flexibility. Recent events include the latest financial filing, which shows a stable but not accelerating revenue trend. No material earnings call transcripts or regulatory filings have been disclosed in the input data. Analysts have not issued any recent upgrades or downgrades, maintaining a neutral stance.